Literature DB >> 18416656

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

Norbert Müller1, Rebecca Schennach, Michael Riedel, Hans-Jürgen Möller.   

Abstract

Major depressive disorder (MDD) is one of the most disabling disorders. Antidepressant pharmacotherapy is currently effective in approximately 70% of all treated cases; the potential superiority of a dual mechanism of pharmacological action (e.g., inhibiting the reuptake of serotonin and norepinephrine) is widely known. Duloxetine, a novel dual acting, selective serotonin and norepinephrine reuptake inhibitor, has demonstrated clinical efficacy in the treatment of MDD and general anxiety disorder (GAD). Duloxetine has been found to be safe and well tolerated, with mild-to-moderate adverse events, a favorable cardiovascular and sexual dysfunction profile, and minor influence on weight gain. The efficacy of duloxetine in the treatment of MDD has been established in randomized, double-blind, placebo-controlled studies. In addition to improving classical emotional symptoms of MDD, duloxetine has in particular beneficial effects on somatic symptoms of depression including pain. The superiority of duloxetine was shown over placebo, while comparison studies with other antidepressants showed only partial superiority. Randomized clinical trials in GAD also provide evidence for beneficial effects compared with placebo and improvement in quality of life, wellbeing and general health. Moreover, duloxetine is effective and well tolerated in the treatment of diabetic peripheral neuropathic pain and stress urinary incontinence. First results indicate that duloxetine might also be effective in the treatment of children with depression and pain. Overall, duloxetine is an interesting novel treatment option in the management of major depression and has shown efficacy in a broad range of diseases. It therefore may provide additional benefit to current therapeutic options in the treatment of psychiatric, internal, as well as urological disorders such as spinal dysfunctions. Due to duloxetine's properties, a wide range of use will be encountered in the mid-to-long term.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18416656     DOI: 10.1586/14737175.8.4.527

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  4 in total

1.  Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis.

Authors:  Yong-Hai Sun; Yu-Lin Dong; Yu-Tong Wang; Guo-Li Zhao; Gui-Jun Lu; Jing Yang; Sheng-Xi Wu; Ze-Xu Gu; Wen Wang
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

2.  Psychiatric disorders in children and adolescents presenting with unexplained chronic pain: what is the prevalence and clinical relevancy?

Authors:  Lidewij M E Knook; Antoinette Y Konijnenberg; Joost van der Hoeven; Jan L L Kimpen; Jan K Buitelaar; Herman van Engeland; Elisabeth R de Graeff-Meeder
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-12-21       Impact factor: 4.785

3.  Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice.

Authors:  Marco Redaelli; María Jimena Ricatti; Marialaura Simonetto; Mirko Claus; Maurizio Ballabio; Antonio Caretta; Carla Mucignat-Caretta
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

4.  Small compounds mimicking the adhesion molecule L1 improve recovery in a zebrafish demyelination model.

Authors:  Suhyun Kim; Dong-Won Lee; Melitta Schachner; Hae-Chul Park
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.